UBS AM
ACRS icon

UBS AM’s Aclaris Therapeutics ACRS Stock Holding History

UBS AM’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-113,601
Closed -$119K – 2520
2023
Q4 		$119K Hold
113,601
– – ﹤0.01% 2520
2023
Q3 		$778K Buy
113,601
+25,585
+29% +$219K ﹤0.01% 2092
2023
Q2 		$712K Hold
88,016
– – ﹤0.01% 2162
2023
Q1 		$712K Hold
88,016
– – ﹤0.01% 2162
2022
Q4 		$1.39M Buy
88,016
+1,310
+2% +$21.1K ﹤0.01% 1700
2022
Q3 		$1.36M Buy
86,706
+439
+0.5% +$6.92K ﹤0.01% 1792
2022
Q2 		$1.2M Buy
86,267
+36,921
+75% +$517K ﹤0.01% 1859
2022
Q1 		$851K Hold
49,346
– – ﹤0.01% 2224
2021
Q4 		$717K Buy
49,346
+12,880
+35% +$195K ﹤0.01% 2381
2021
Q3 		$656K Buy
36,466
+5,186
+17% +$83.1K ﹤0.01% 2374
2021
Q2 		$549K Buy
+31,280
New +$711K ﹤0.01% 2502
2019
Q2 		– Sell
-11,368
Closed -$68.1K – 2856
2019
Q1 		$68.1K Buy
+11,368
New +$75.4K ﹤0.01% 2592
2018
Q1 		– Sell
-9,568
Closed -$236K – 2654
2017
Q4 		$236K Sell
9,568
-224,028
-96% -$5.46M ﹤0.01% 2227
2017
Q3 		$6.03M Buy
233,596
+123,559
+112% +$3.31M 0.01% 1027
2017
Q2 		$2.98M Buy
+110,037
New +$2.99M ﹤0.01% 1215

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM's ACRS Position: Q1 2024 in Review

UBS AM sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 113,601 shares — an estimated $119K sold.

UBS AM first reported a position in ACRS in Q2 2017 and held it in 15 quarters. The position peaked at $6.03M in Q3 2017. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • UBS AM reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • UBS AM sold 113,601 Aclaris Therapeutics shares in Q1 2024, an estimated $119K.
  • UBS AM first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 15 quarters.
  • UBS AM's Aclaris Therapeutics position peaked at $6.03M in Q3 2017.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.